ELTP posts record fiscal 2025 revenues and operating income gains, fueled by new launches and expanding generics market share.
Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Q4 2025 Earnings Conference Call July 1, 2025 11:30 AM ET Company Participants Carter J. Ward - CFO, Secretary & Treasurer Nasrat Hakim - Chairman, CEO & President Operator Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals Conference Call.
Conference Call Scheduled for Tuesday, July 1 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - June 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2025 ("Fiscal 2025"). Consolidated revenues for Fiscal 2025 were $84.0 million, an increase of $27.4 million or approximately 48% as compared to the comparable period of the prior fiscal year.
12 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
12 Feb 2025 Date | | - Cons. EPS | - EPS |
14 Nov 2024 Date | | - Cons. EPS | - EPS |
14 Aug 2024 Date | | - Cons. EPS | 0 EPS |
29 Jun 2024 Date | | - Cons. EPS | - EPS |
12 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
12 Feb 2025 Date | | - Cons. EPS | - EPS |
14 Nov 2024 Date | | - Cons. EPS | - EPS |
14 Aug 2024 Date | | - Cons. EPS | 0 EPS |
29 Jun 2024 Date | | - Cons. EPS | - EPS |
Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Nasrat Hakim CEO | OTCQB Exchange | US28659T2006 ISIN |
US Country | 53 Employees | - Last Dividend | - Last Split | 23 Jul 1998 IPO Date |
Elite Pharmaceuticals, Inc. is a distinguished specialty pharmaceutical company focused on the development, manufacturing, and marketing of oral, controlled-release, and generic pharmaceuticals. The company is actively involved in two major pharmaceutical segments: Abbreviated New Drug Applications (ANDAs) for Generic Pharmaceuticals and New Drug Applications (NDAs) for Branded Pharmaceuticals. Since its inception in 1997, Elite Pharmaceuticals has been committed to providing advanced therapeutic solutions and has established itself as a player in the pharmaceutical industry with a robust product portfolio and a pipeline of developed drugs. Headquartered in Northvale, New Jersey, Elite Pharmaceuticals strives to address the needs of patients across various therapeutic areas with its innovative drug delivery technologies and manufacturing capabilities.
Elite Pharmaceuticals offers a comprehensive range of generic and branded pharmaceutical products targeting a variety of therapeutic areas. The company leverages its expertise in oral dose pharmaceuticals to serve the bariatric, pain management, cardiovascular, central nervous system, muscle relaxant, antipsychotic, and antibiotic sectors, among others. Below is an outline of their key products and services:
In addition to its comprehensive portfolio, Elite Pharmaceuticals actively engages in the contract manufacturing of controlled-release products for third-party clients, covering pain, allergy, bariatric, attention deficit, and infection therapies. Furthermore, the company is at the forefront of developing abuse-deterrent opioid products, reflecting its commitment to addressing the ongoing opioid crisis while meeting medical needs.